Q32 Bio, Inc. Hits New 52-Week High of $13.15

Q32 Bio, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 13.15 on May 27, 2026. This achievement marks a notable increase from its 52-week low of USD 1.35, showcasing a remarkable recovery and growth trajectory over the past year. The company's performance over the last year has outpaced the S&P 500, with a reported increase of 27%. Despite being in a loss-making position, Q32 Bio's market capitalization stands at USD 92 million, reflecting its status as a microcap entity within the industry. The company currently has a debt-to-equity ratio of 2.01, indicating a higher level of debt relative to equity, which is a critical factor for investors to consider. As Q32 Bio continues to navigate the competitive landscape of pharmaceuticals and biotechnology, its recent price movement highlights the dynamic nature of the market and the potential for further developments in the company's operations.